Literature DB >> 32332286

The impact of intra-arrest hypothermia.

Per Nordberg1, Filippo Annoni2, Fabio S Taccone2.   

Abstract

PURPOSE OF REVIEW: To address the impact of therapeutic hypothermia induced already during cardiopulmonary resuscitation (i.e. intra-arrest cooling) and its association with neurologic functional outcome. RECENT
FINDINGS: Intra-arrest cooling is superior than post-ROSC cooling to mitigate brain injuries in experimental models of cardiac arrest. The delayed initiation of hypothermia in human studies may not have adequately addressed the underlying pathophysiology of ischemia and reperfusion. The assessment of early initiation of cooling has been complicated by increased rate of hemodynamic adverse events caused by infusion of cold intravenous fluids. These adverse events have been more deleterious in patients with initial shockable rhythms. A recent randomized study shows that an alternative intra-arrest cooling method using trans-nasal evaporative cooling was well tolerated and effective to shorten time to target temperature. However, the neurologic outcomes (CPC 1-2 at 90 days) in favor of intra-arrest cooling compared to hospital cooling (34.8% vs 25.9%, P = 0.11) in patients with initial shockable rhythms did not reach statistical significance.
SUMMARY: Therapeutic intra-arrest hypothermia can be initiated safely at the scene of the arrest using transnasal evaporative cooling. The potential beneficial effect of intra-arrest cooling on neurologic recovery in patients with initial shockable rhythms should be explored further.

Entities:  

Mesh:

Year:  2020        PMID: 32332286     DOI: 10.1097/MCC.0000000000000724

Source DB:  PubMed          Journal:  Curr Opin Crit Care        ISSN: 1070-5295            Impact factor:   3.687


  1 in total

1.  Evidence Summary of Temperature Management for Comatose Patients after Cardiopulmonary Resuscitation in ICUs.

Authors:  Zhuo Yang; Ting Ni; Yan Yang; Hui Zhang; Hongli Chi
Journal:  Appl Bionics Biomech       Date:  2022-06-30       Impact factor: 1.664

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.